← All trials
NCT03187509
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2018
- Primary completion
- Mar 14, 2022
- Completion date
- Mar 14, 2022
- First posted
- Jun 15, 2017
- Last posted
- Mar 15, 2022
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- New York City Health and Hospitals CorporationLead sponsor
- Yeshiva UniversityOverall official - principal investigator
- New York City Health and Hospitals CorporationReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.